Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20899224 | 1.00 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL1582585 | 0.98 | CYP3A4 (0.39) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL29863987 | 0.96 | CYP3A4 (0.35) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL34871 | 0.95 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL301035 | 0.95 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL301069 | 0.95 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL13456274 | 0.95 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL30858461 | 0.95 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| Lithium SCHEMBL30167974 | 0.95 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL9634685 | 0.93 | CYP3A4 (0.36) | CYP3A4TDP1GAAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-120152713-A | Tricyclic aryl derivatives and compositions and methods thereof | 昂胜医疗科技公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4561563-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561562-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119947718-A | Tricyclic aryl derivatives, and compositions and methods thereof | 昂胜医疗科技公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025085233-A1 | NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025015268-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024165050-A1 | PROTEOLYSIS-TARGETING CHIMERA (PROTAC) COMPOUNDS AND USES THEREOF FIELD | AUBRAK THERAPEUTICS (CN) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024026129-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026128-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | CYP3A4 4666/4885TDP1 2600/4885GAA 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.